Treatment efficacy of dupilumab in a hyper-immunoglobulin E syndrome patient with severe atopic dermatitis
نویسندگان
چکیده
منابع مشابه
Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.
BACKGROUND Dupilumab, a fully human monoclonal antibody that blocks interleukin-4 and interleukin-13, has shown efficacy in patients with asthma and elevated eosinophil levels. The blockade by dupilumab of these key drivers of type 2 helper T-cell (Th2)-mediated inflammation could help in the treatment of related diseases, including atopic dermatitis. METHODS We performed randomized, double-b...
متن کاملEfficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults
Objective Atopic dermatitis is a chronic, relapsing inflammatory skin disease characterized by intense pruritus, excoriations and limited therapies. Dupilumab, a monoclonal antibody against interleukin-4 receptor alpha, is a promising new treatment option for atopic dermatitis. We sought to systematically summarize the efficacy, safety, and influence on quality of life of dupilumab for the trea...
متن کاملThe efficacy of phototherapy in treatment of resistant Atopic dermatitis
Background: Due to the chronic nature of atopic dermatitis and dependence of most patients to steroids, finding a suitable alternative treatment is important. Objectives: To determine the efficacy of phototherapy in treatment of atopic dermatitis, also to evaluate possible influencing factors in response of patients to psoralen+UVA (PUVA) therapy. Patients and Methods: 13 patients with resistan...
متن کاملEconomic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults
INTRODUCTION Dupilumab significantly improves signs and symptoms of atopic dermatitis (AD), including pruritus, symptoms of anxiety and depression, and health-related quality of life versus placebo in adults with moderate-to-severe AD. Since the cost-effectiveness of dupilumab has not been evaluated, the objective of this analysis was to estimate a value-based price range in which dupilumab wou...
متن کاملAlopecia areata after dupilumab for atopic dermatitis
AA: alopecia areata AD: atopic dermatitis IL: interleukin Th: T helper INTRODUCTION Dupilumab is the first targeted biologic therapy approved for the treatment of atopic dermatitis (AD). More than 1,000 adult patient exposures formed the basis of its approval in March 2017 for the treatment of moderate-to-severe AD not well controlled with topical therapies or when other therapies are inadvisab...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: JAAD Case Reports
سال: 2021
ISSN: 2352-5126
DOI: 10.1016/j.jdcr.2021.03.007